O
OriginCell
A biomedical equipment enterprise that develops tumor immuno-therapy solutions
About OriginCell
Shanghai OriginCell Biological Cryo Equipment Co., Ltd. operates as a specialized subsidiary of the OriginCell Technology Group, focusing on the biomedical equipment sector. The company was established in 2017, incubated by its parent group, which was co-founded in 2014 by veteran entrepreneur Mr. Qu Jianguo and the publicly listed company Canature Health (300272). Mr. Qu, a notable figure who has successfully founded two other listed companies, serves as the Chairman and Chief Engineer of OriginCell, channeling his extensive entrepreneurial experience into the life sciences field. His journey began with founding a township enterprise in 1973 and later establishing 'Shenhua Industrial', one of the first eight companies listed on the A-share market. In 2014, he ventured into the health industry by founding the OriginCell Technology Group.
Read full description
The firm's core business revolves around the research, development, design, and manufacturing of advanced automated cryogenic storage equipment for biological samples. This addresses the critical need for reliable and efficient cryopreservation in the biomedical industry. The business model integrates hardware manufacturing with comprehensive service provisions, offering clients holistic solutions for their biobanking needs. Revenue is generated from selling this specialized equipment and providing full-process, one-stop services that include the planning, construction, management, and maintenance of biological sample and cell banks. Key clients include research hospitals, biomedical R&D enterprises, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), life science research institutions, and university medical schools.
OriginCell's product portfolio is designed to create a complete, automated, and intelligent solution for the entire bio-sample lifecycle. This includes automated storage systems for both ultra-low (-80°C) and deep cryogenic (-196°C) temperatures, covering both vapor-phase and liquid-phase liquid nitrogen environments. A standout product is the BSN series, a honeycomb-style automated storage system that ensures sample safety and minimizes cross-contamination. The company also provides auxiliary equipment such as controlled-rate freezers, automated thawing systems, intelligent transport robots (AGVs/RGVs), and a 5G-IoT remote management software platform called OBS-CybeBiobank5G-IoT for unmanned, intelligent sample bank operation. This integrated approach aims to standardize and automate cryopreservation, liberating scientists from manual labor and enhancing the quality and safety of stored biological samples.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Tangshan City, China
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2016
- Capital deployed
- $0
- Preferred round
- Unknown
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2022 | $120M | $480M | Qiming Venture Partners · Quan Capital | ↗ |
| SERIES AOther financing | May 2022 | $56M | $226M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for OriginCell is 300 monthly website visits, down 14.3% over the last three months. OriginCell's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Qiming Venture Partners
Quan Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OriginCell on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OriginCell’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







